$EXEL
EXELIXIS, INC.

2014 Q4 Form 10-Q Financial Statement

#000093976714000067 Filed on November 04, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $7.353M $6.291M $5.466M
YoY Change 69.15% 15.09% -58.94%
Cost Of Revenue $700.0K $573.0K $290.0K
YoY Change 133.33% 97.59%
Gross Profit $6.669M $5.718M $5.176M
YoY Change 63.3% 10.47% -61.12%
Gross Profit Margin 90.7% 90.89% 94.69%
Selling, General & Admin $9.800M $9.906M $13.60M
YoY Change -27.94% -27.15% 85.18%
% of Gross Profit 146.95% 173.24% 262.71%
Research & Development $39.70M $43.63M $47.35M
YoY Change -19.96% -7.87% 54.35%
% of Gross Profit 595.29% 762.99% 914.88%
Depreciation & Amortization -$600.0K $1.900M $800.0K
YoY Change -185.71% 137.5% -46.67%
% of Gross Profit -9.0% 33.23% 15.46%
Operating Expenses $49.40M $57.87M $61.38M
YoY Change -21.96% -5.73% 58.37%
Operating Profit -$46.21M -$51.57M -$55.91M
YoY Change -21.97% -7.76% 119.76%
Interest Expense -$11.90M $12.28M $11.43M
YoY Change 5.31% 7.45% 48.85%
% of Operating Profit
Other Income/Expense, Net -$10.99M -$11.21M
YoY Change -2.01% 52.3%
Pretax Income -$58.10M -$62.60M -$67.12M
YoY Change -17.94% -6.74% 104.62%
Income Tax -$200.0K $0.00
% Of Pretax Income
Net Earnings -$57.95M -$62.56M -$67.12M
YoY Change -18.08% -6.8% 104.56%
Net Earnings / Revenue -788.15% -994.44% -1228.03%
Basic Earnings Per Share
Diluted Earnings Per Share -$296.5K -$320.9K -$364.5K
COMMON SHARES
Basic Shares Outstanding 195.2M shares 195.1M shares 184.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $144.3M $192.0M $279.2M
YoY Change -40.49% -31.23% -40.89%
Cash & Equivalents $80.40M $100.1M $92.02M
Short-Term Investments $63.90M $91.90M $187.2M
Other Short-Term Assets $15.70M $20.10M $20.00M
YoY Change -9.25% 0.5% 9.29%
Inventory $2.381M $3.876M $1.764M
Prepaid Expenses
Receivables $4.900M $4.700M $5.200M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $167.2M $220.7M $306.2M
YoY Change -37.27% -27.92% -37.95%
LONG-TERM ASSETS
Property, Plant & Equipment $2.432M $2.928M $5.520M
YoY Change -50.47% -46.96% -12.27%
Goodwill $63.68M $63.68M $63.68M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $81.60M $84.60M $157.4M
YoY Change -43.45% -46.25% -2.96%
Other Assets $3.649M $7.101M $7.300M
YoY Change -47.02% -2.73% -19.98%
Total Long-Term Assets $156.0M $163.0M $249.8M
YoY Change -34.08% -34.75% -7.21%
TOTAL ASSETS
Total Short-Term Assets $167.2M $220.7M $306.2M
Total Long-Term Assets $156.0M $163.0M $249.8M
Total Assets $323.3M $383.7M $556.0M
YoY Change -35.77% -30.99% -27.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.413M $3.362M $3.559M
YoY Change -31.38% -5.54% 9.64%
Accrued Expenses $41.55M $45.10M $35.04M
YoY Change 18.84% 28.71% 47.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $97.83M $97.25M $12.13M
YoY Change 731.75% 701.95% -8.13%
Total Short-Term Liabilities $170.4M $173.9M $77.88M
YoY Change 93.99% 123.31% -8.82%
LONG-TERM LIABILITIES
Long-Term Debt $259.1M $258.0M $329.5M
YoY Change -22.76% -21.7% 2.29%
Other Long-Term Liabilities $4.169M $4.772M $5.726M
YoY Change -10.8% -16.66% -26.29%
Total Long-Term Liabilities $263.3M $262.7M $335.2M
YoY Change -22.59% -21.62% 4215.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $170.4M $173.9M $77.88M
Total Long-Term Liabilities $263.3M $262.7M $335.2M
Total Liabilities $482.6M $442.2M $423.2M
YoY Change -0.18% 4.48% 0.34%
SHAREHOLDERS EQUITY
Retained Earnings -$1.751B -$1.709B -$1.428B
YoY Change 17.54% 19.7% 18.82%
Common Stock $196.0K $195.0K $184.0K
YoY Change 6.52% 5.98% 0.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$114.8M -$58.50M $132.8M
YoY Change
Total Liabilities & Shareholders Equity $323.3M $383.7M $556.0M
YoY Change -35.77% -30.99% -27.1%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$57.95M -$62.56M -$67.12M
YoY Change -18.08% -6.8% 104.56%
Depreciation, Depletion And Amortization -$600.0K $1.900M $800.0K
YoY Change -185.71% 137.5% -46.67%
Cash From Operating Activities -$50.00M -$58.00M -$57.00M
YoY Change 5.49% 1.75% 67.65%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$200.0K -$700.0K
YoY Change -100.0% -71.43% -30.0%
Acquisitions
YoY Change
Other Investing Activities $30.20M $11.20M $18.70M
YoY Change -49.33% -40.11% -113.34%
Cash From Investing Activities $30.10M $11.20M $18.00M
YoY Change -49.5% -37.78% -112.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K -300.0K -800.0K
YoY Change -150.0% -62.5% -100.19%
NET CHANGE
Cash From Operating Activities -50.00M -58.00M -57.00M
Cash From Investing Activities 30.10M 11.20M 18.00M
Cash From Financing Activities 100.0K -300.0K -800.0K
Net Change In Cash -19.80M -47.10M -39.80M
YoY Change -265.0% 18.34% -116.54%
FREE CASH FLOW
Cash From Operating Activities -$50.00M -$58.00M -$57.00M
Capital Expenditures $0.00 -$200.0K -$700.0K
Free Cash Flow -$50.00M -$57.80M -$56.30M
YoY Change 5.71% 2.66% 70.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3786000 USD
CY2014Q1 us-gaap Share Price
SharePrice
8
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.13
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9345000 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3362000 USD
CY2014Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6441000 USD
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
12797000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34958000 USD
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45102000 USD
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
146000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1564670000 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1650621000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8454000 USD
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
714000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8490000 USD
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2893000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
19445000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
21826000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
110977000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
81258000 shares
CY2014Q3 us-gaap Assets
Assets
383656000 USD
CY2013Q4 us-gaap Assets
Assets
503287000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
220670000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
266609000 USD
CY2013Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
409966000 USD
CY2014Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
289743000 USD
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
409966000 USD
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
289743000 USD
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
300000 USD
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
213000 USD
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
55000 USD
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
81000 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
409721000 USD
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
289611000 USD
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
64600000 USD
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
21792000 USD
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
267951000 USD
CY2014Q3 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
35 investment
CY2014Q3 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 investment
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103978000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100065000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92016000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
170069000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3913000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-78053000 USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
184533651 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
195179456 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
195179456 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
184533651 shares
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
195000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
184000 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62713000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-210711000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-173742000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66681000 USD
CY2013Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
10000000 USD
CY2014Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
96496000 USD
CY2014Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
177962000 USD
CY2013Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
255147000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1359000 USD
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
290000 USD
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
573000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
855000 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2762000 USD
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1319000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1450000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2382000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3014000 USD
CY2014Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
846000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.95
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1916000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fiscal Period
FiscalPeriod
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exelixis adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31st. Fiscal year 2013, a 52-week year, ended on December&#160;27, 2013, and fiscal year 2014, a 53-week year, will end on January 2, 2015. For convenience, references in this report as of and for the fiscal periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;26, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">September&#160;27, 2013</font><font style="font-family:inherit;font-size:10pt;">, and as of the fiscal year ended December&#160;27, 2013, are indicated as ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, and December&#160;31, 2013, respectively.</font></div></div>
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
838000 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0 USD
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0 USD
CY2014Q3 us-gaap Goodwill
Goodwill
63684000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
63684000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
781000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
2420000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11600000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-652000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10144000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
14482000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-15304000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-131000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1764000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
986000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-530000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-756000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2834000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1495000 USD
us-gaap Increase Decrease In Restricted Cash And Investments
IncreaseDecreaseInRestrictedCashAndInvestments
-20397000 USD
us-gaap Increase Decrease In Restricted Cash And Investments
IncreaseDecreaseInRestrictedCashAndInvestments
-15968000 USD
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-2705000 USD
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-5320000 USD
us-gaap Interest Expense
InterestExpense
36125000 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
12282000 USD
us-gaap Interest Expense
InterestExpense
33726000 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
11430000 USD
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
81000 USD
CY2014Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
588000 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
3876000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
2890000 USD
CY2014Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
787000 USD
CY2013Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
529000 USD
CY2014Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2501000 USD
CY2013Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2280000 USD
CY2014Q3 us-gaap Liabilities
Liabilities
442167000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
437049000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
503287000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
383656000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
87853000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
173912000 USD
CY2014Q3 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
846000 USD
CY2014Q3 us-gaap Long Term Debt
LongTermDebt
355215000 USD
CY2013Q4 us-gaap Long Term Debt
LongTermDebt
347237000 USD
CY2014Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
97253000 USD
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
11762000 USD
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
335475000 USD
CY2014Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
257962000 USD
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
144299000 USD
CY2014Q3 us-gaap Long Term Investments
LongTermInvestments
84589000 USD
CY2014Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
80000000 USD
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
80328000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65362000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-11455000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
84846000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
116154000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-185429000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-151444000 USD
us-gaap Net Income Loss
NetIncomeLoss
-174014000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-62560000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-67124000 USD
us-gaap Net Income Loss
NetIncomeLoss
-210589000 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11211000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32339000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32796000 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10986000 USD
CY2014Q3 us-gaap Notes Payable Current
NotesPayableCurrent
757000 USD
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1762000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Operating Expenses
OperatingExpenses
196008000 USD
us-gaap Operating Expenses
OperatingExpenses
168209000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
61379000 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
57865000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-51574000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-178250000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-141218000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-55913000 USD
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13855000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13116000 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7101000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6888000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
272000 USD
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
443000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-122000 USD
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-153000 USD
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4772000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4674000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5243000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3602000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
930000 USD
CY2013Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
219000 USD
CY2014Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1296000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
176768000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
109237000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2079000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
452000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
8184000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
3785000 USD
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5112000 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7860000 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
838000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75646000 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75600000 USD
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-12374000 USD
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-11333000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
251470000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
212506000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
286000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
40000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
894000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
929000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2928000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4910000 USD
CY2014Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
4722000 USD
CY2013Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
3941000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43628000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
149451000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47354000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
129166000 USD
CY2014Q3 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
12210000 USD
CY2013Q4 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
12213000 USD
CY2014Q3 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
4684000 USD
CY2013Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
16897000 USD
CY2013Q3 us-gaap Restructuring Charges
RestructuringCharges
137000 USD
us-gaap Restructuring Charges
RestructuringCharges
4135000 USD
us-gaap Restructuring Charges
RestructuringCharges
865000 USD
CY2014Q3 us-gaap Restructuring Charges
RestructuringCharges
3758000 USD
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
667000 USD
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 USD
CY2013Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
4425000 USD
CY2014Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
6580000 USD
CY2013Q4 us-gaap Restructuring Reserve Noncurrent
RestructuringReserveNoncurrent
9047000 USD
CY2014Q3 us-gaap Restructuring Reserve Noncurrent
RestructuringReserveNoncurrent
5521000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1498762000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1709351000 USD
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6291000 USD
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
4771000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
10670000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
17758000 USD
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
6291000 USD
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
5466000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
17758000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
26991000 USD
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y2M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y9M21D
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
138475000 USD
CY2014Q3 us-gaap Short Term Investments
ShortTermInvestments
91937000 USD
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
10000000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
19090 shares
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
66238000 USD
CY2014Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-58511000 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
23983275 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.18
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.48
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.28
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.31
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.53
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9906000 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13598000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37323000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
41063000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8454000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8503000 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
15478788 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
669778 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
882864 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
9653615 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
32065158 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">The preparation of our consolidated financial statements is in conformity with accounting principles generally accepted in the United States which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to inventory, revenue recognition, valuation of long-lived assets, certain accrued liabilities including clinical trial accruals and restructuring liability, valuation of warrants, share-based compensation and the valuation of the debt and equity components of our convertible debt at issuance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. </font><font style="font-family:inherit;font-size:10pt;">Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
183957000 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
195126000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
193855000 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
184149000 shares
exel Annual Operating Cycle
AnnualOperatingCycle
P364D
exel Annual Operating Cycle
AnnualOperatingCycle
P371D
CY2014Q3 exel Cash Cash Equivalentsand Availableforsale Securities
CashCashEquivalentsandAvailableforsaleSecurities
293485000 USD
CY2013Q4 exel Cash Cash Equivalentsand Availableforsale Securities
CashCashEquivalentsandAvailableforsaleSecurities
415862000 USD
CY2014Q3 exel Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis
CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis
293353000 USD
CY2013Q4 exel Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis
CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis
415617000 USD
CY2014Q3 exel Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments
CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments
213000 USD
CY2013Q4 exel Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments
CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments
300000 USD
CY2014Q3 exel Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments
CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments
81000 USD
CY2013Q4 exel Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments
CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments
55000 USD
exel Debt Collateral Number Of Affiliate Banks
DebtCollateralNumberOfAffiliateBanks
1 affiliate
exel Debt Collateral Number Of Required Investment Accounts
DebtCollateralNumberOfRequiredInvestmentAccounts
1 account
exel License Contractand Collaboration Reimbursement Revenue
LicenseContractandCollaborationReimbursementRevenue
16321000 USD
exel License Contractand Collaboration Reimbursement Revenue
LicenseContractandCollaborationReimbursementRevenue
0 USD
CY2013Q3 exel License Contractand Collaboration Reimbursement Revenue
LicenseContractandCollaborationReimbursementRevenue
695000 USD
CY2014Q3 exel License Contractand Collaboration Reimbursement Revenue
LicenseContractandCollaborationReimbursementRevenue
0 USD
CY2014Q3 exel Numberof Phase3 Trialsin Process
NumberofPhase3TrialsinProcess
3 trial
CY2014Q3 exel Numberof Trialsin Process
NumberofTrialsinProcess
45 trial
exel Proceeds From Exercise Of Stock Options And Warrants Net Of Repurchases
ProceedsFromExerciseOfStockOptionsAndWarrantsNetOfRepurchases
25000 USD
exel Proceeds From Exercise Of Stock Options And Warrants Net Of Repurchases
ProceedsFromExerciseOfStockOptionsAndWarrantsNetOfRepurchases
120000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--01-02
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000939767
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
195215795 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
EXELIXIS, INC.
dei Trading Symbol
TradingSymbol
exel

Files In Submission

Name View Source Status
0000939767-14-000067-index-headers.html Edgar Link pending
0000939767-14-000067-index.html Edgar Link pending
0000939767-14-000067.txt Edgar Link pending
0000939767-14-000067-xbrl.zip Edgar Link pending
exel-20140926.xml Edgar Link completed
exel-20140926.xsd Edgar Link pending
exel-20140926_cal.xml Edgar Link unprocessable
exel-20140926_def.xml Edgar Link unprocessable
exel-20140926_lab.xml Edgar Link unprocessable
exel-20140926_pre.xml Edgar Link unprocessable
exel2014093010-q.htm Edgar Link pending
exel20140930exhibit121.htm Edgar Link pending
exel20140930exhibit311.htm Edgar Link pending
exel20140930exhibit312.htm Edgar Link pending
exel20140930exhibit321.htm Edgar Link pending
exel20149030exhibit101.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending